First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.

Two masked bispecific antibodies, licensed for $100m, produce promising early data.

Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.

Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.

The private group taps DualityBio for an EGFR x HER3 ADC.

The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.

Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.